Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This pilot study found elevated levels of leptin and other proinflammatory molecules in the serum of melanoma patients, suggesting a potential role for leptin in melanoma progression and a possibility for targeting it in adjuvant therapy.

Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.

This case report describes a 19-year-old female with systemic lupus erythematosus who exhibited eyelash trichomegaly, a rare disorder involving changes in eyelash characteristics, alongside diffuse alopecia.

This study suggests that epidermal turnover could be a regulated mechanism of iron excretion, with systemic iron levels influencing keratinocyte behavior and differentiation markers in the skin.

Terbinafine is the most effective medicine for fungal nail infections, especially for diabetics and those with weak immune systems.

This phase II study found that gemcitabine plus paclitaxel showed promising activity and manageable toxicity as first-line therapy for recurrent or metastatic breast cancer, with a 35% overall response rate.

A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.

This study reported that inpatient dermatology consultations at a large tertiary care center led to treatment changes in 81.9% of cases, particularly improving management of complex cutaneous conditions associated with systemic diseases.

This figure in the publication investigates the relationship between expression levels and tumor burden but reports no specific findings or conclusions.

This study conducted in an Iraqi oncology setting found generic Palbociclib to have a safety profile consistent with previous data, with observed side effects including high rates of neutropenia and anemia, particularly among patients receiving it with Fulvestrant.

This review discusses nanoparticle systems for cancer treatment and reports no new clinical results; the authors emphasize their potential to reduce systemic toxicity and call for further development.

This chapter reviews the skin side effects associated with targeted cancer therapies and emphasizes the importance of collaboration between oncologists and dermatologists without reporting new results.

This review discusses skin signs that can indicate systemic diseases and provides no new clinical results; it aims to aid physicians in diagnosing these conditions.

This case study reports the rare occurrence of widespread soft-tissue calcification in a young patient with SLE, suggesting that 99mTe-phosphate compounds could help diagnose this complication.

In this case report, a patient with Cronkhite-Canada Syndrome developed colon cancer and liver metastasis despite hormone therapy, highlighting the need for regular monitoring and early detection strategies.

In this case report, a 40-year-old woman with systemic lupus erythematosus developed calcinosis cutis, a rare complication characterized by calcified deposits in her legs, requiring surgical intervention and ongoing medical treatment due to infection.

This study found that in first-line treatment of metastatic breast cancer, pegylated liposomal doxorubicin (PLD) provided similar progression-free survival to doxorubicin with significantly less cardiotoxicity.

This review discusses the properties and therapeutic potentials of beta-sitosterol, highlighting a need for more detailed studies on its mechanisms and long-term effects in humans; it reports no new results.

This study observed that the NOTCH signaling pathway may contribute to the development of fibrosis in systemic sclerosis by affecting epithelial cell changes, and inhibiting this pathway could prevent fibrosis in experimental models.

This review evaluates photobiomodulation's diverse clinical uses in sports and medicine, reporting physiological modulation and potential therapeutic benefits, but emphasizes the importance of precise dosimetry for success.

This review discusses the cutaneous side effects associated with vemurafenib and ipilimumab in metastatic melanoma treatment and emphasizes the importance of dermatologists in managing these skin eruptions; it reports no new clinical results.

This study identified that a deficiency in the palmitoyl transferase enzyme, due to a mutation in the Zdhhc13 gene, led to severe physiological abnormalities in mice, including skin, bone, and systemic amyloid issues.

This study found that while cyclophosphamide remains effective for severe autoimmune conditions, it is associated with gastrointestinal side effects, infections, some cases of irreversible amenorrhoea, and a higher risk of malignancies, emphasizing the need for long-term monitoring.

In this prospective phase II clinical trial, researchers are investigating whether adding dutasteride to combined androgen blockade can improve the response rate and clinical outcomes for patients with androgen receptor-positive recurrent or metastatic salivary duct carcinoma.

This case report involves a 56-year-old woman with idiopathic thrombocytopenic purpura and scarring alopecia, suggesting diagnoses including discoid lupus erythematosus and lichen planopilaris without presenting new clinical findings.

This review summarizes common skin-related side effects of BRAF inhibitors and immunotherapy in advanced melanoma treatment, reporting no new clinical findings, and emphasizes consensus management to improve patient outcomes.

This case report describes the first successful use of telitacicept in treating a patient with systemic lupus erythematosus and a history of papillary thyroid carcinoma, suggesting its potential as a therapeutic option for such conditions.

This retrospective study found a variety of dermatological adverse events associated with antineoplastic treatments, often leading to changes or suspension of cancer therapies in affected patients.

Early diagnosis and aggressive treatment are crucial for Cicatricial Alopecia, and treatment effectiveness varies among patients.

This report highlights Amvuttra's approval for hATTR amyloidosis as a more convenient RNAi therapy, and Olumiant's attention as the first systemic drug for hair loss among recent developments.